Related Articles
Outcome of third‑line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma
Expression of total and phospho 4EBP1 in metastatic and non‑metastatic renal cell carcinoma
Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report
Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma